Literature DB >> 35755088

Joint modelling of longitudinal response and time-to-event data using conditional distributions: a Bayesian perspective.

Srimanti Dutta1, Geert Molenberghs2,3, Arindom Chakraborty1.   

Abstract

Over the last 20 or more years a lot of clinical applications and methodological development in the area of joint models of longitudinal and time-to-event outcomes have come up. In these studies, patients are followed until an event, such as death, occurs. In most of the work, using subject-specific random-effects as frailty, the dependency of these two processes has been established. In this article, we propose a new joint model that consists of a linear mixed-effects model for longitudinal data and an accelerated failure time model for the time-to-event data. These two sub-models are linked via a latent random process. This model will capture the dependency of the time-to-event on the longitudinal measurements more directly. Using standard priors, a Bayesian method has been developed for estimation. All computations are implemented using OpenBUGS. Our proposed method is evaluated by a simulation study, which compares the conditional model with a joint model with local independence by way of calibration. Data on Duchenne muscular dystrophy (DMD) syndrome and a set of data in AIDS patients have been analysed.
© 2021 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  62F15; 62N01; AFT model; Bartlett decomposition; Bayesian; conditional distribution; muscular dystrophy

Year:  2021        PMID: 35755088      PMCID: PMC9225235          DOI: 10.1080/02664763.2021.1897971

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  31 in total

1.  Shrinkage estimators for covariance matrices.

Authors:  M J Daniels; R E Kass
Journal:  Biometrics       Date:  2001-12       Impact factor: 2.571

2.  Bayesian analysis of a disability model for lung cancer survival.

Authors:  C Armero; S Cabras; M E Castellanos; S Perra; A Quirós; M J Oruezábal; J Sánchez-Rubio
Journal:  Stat Methods Med Res       Date:  2012-07-05       Impact factor: 3.021

3.  Inferences for joint modelling of repeated ordinal scores and time to event data.

Authors:  Arindom Chakraborty; Kalyan Das
Journal:  Comput Math Methods Med       Date:  2010-09       Impact factor: 2.238

4.  Personalized screening intervals for biomarkers using joint models for longitudinal and survival data.

Authors:  Dimitris Rizopoulos; Jeremy M G Taylor; Joost Van Rosmalen; Ewout W Steyerberg; Johanna J M Takkenberg
Journal:  Biostatistics       Date:  2015-08-28       Impact factor: 5.899

5.  Multiple-imputation-based residuals and diagnostic plots for joint models of longitudinal and survival outcomes.

Authors:  Dimitris Rizopoulos; Geert Verbeke; Geert Molenberghs
Journal:  Biometrics       Date:  2009-05-18       Impact factor: 2.571

6.  Simultaneously modelling censored survival data and repeatedly measured covariates: a Gibbs sampling approach.

Authors:  C L Faucett; D C Thomas
Journal:  Stat Med       Date:  1996-08-15       Impact factor: 2.373

7.  A Bayesian semiparametric multivariate joint model for multiple longitudinal outcomes and a time-to-event.

Authors:  Dimitris Rizopoulos; Pulak Ghosh
Journal:  Stat Med       Date:  2011-02-21       Impact factor: 2.373

8.  Bayesian joint modeling for assessing the progression of chronic kidney disease in children.

Authors:  Carmen Armero; Anabel Forte; Hèctor Perpiñán; María José Sanahuja; Silvia Agustí
Journal:  Stat Methods Med Res       Date:  2016-03-16       Impact factor: 3.021

9.  Bayesian joint modelling of longitudinal data on abstinence, frequency and intensity of drinking in alcoholism trials.

Authors:  Eugenia Buta; Stephanie S O'Malley; Ralitza Gueorguieva
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2017-11-06       Impact factor: 2.483

10.  Modelling progression of CD4-lymphocyte count and its relationship to survival time.

Authors:  V De Gruttola; X M Tu
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.